Pharmacokinetics and Dose Escalation of the Heat Shock Protein Inhibitor 17-AAG in Combination with Bortezomib in Relapsed or Refractory Acute Myeloid Leukemia

This phase I study was conducted to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of the heat shock protein 90 (HSP90) inhibitor 17-allyamino-17-demethoxygeldanamycin (17-AAG) in combination with bortezomib, and to provide pharmacokinetic data in relapsed or refractor...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Walker, Alison R., Klisovic, Rebecca, Johnston, Jeffrey S., Jiang, Yao, Geyer, Susan, Kefauver, Cheryl, Binkley, Philip, Byrd, John C., Grever, Michael R., Garzon, Ramiro, Phelps, Mitch A., Marcucci, Guido, Blum, Kristie A., Blum, William
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2013
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3860322/
https://ncbi.nlm.nih.gov/pubmed/23256542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2012.760733
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi